Antibodies News and Research

RSS

Evolutionary gene mutation unique to humans may be to blame for risk of advanced cancers

Compared to chimpanzees, our closest evolutionary cousins, humans are particularly prone to developing advanced carcinomas -- the type of tumors that include prostate, breast, lung and colorectal cancers -- even in the absence of known risk factors, such as genetic predisposition or tobacco use.

9 Dec 2020

UC Davis Health joins with Novavax to test a new experimental coronavirus vaccine

Despite the encouraging news of potentially successful COVID-19 vaccine trials, there is not yet an FDA-approved vaccine available. Research into other effective coronavirus vaccines continues, including at UC Davis Health.

8 Dec 2020

High-performing multi-immunoassay for early diagnosis and prognosis of COVID-19

A new study published on the preprint server bioRxiv in December 2020 indicates the ability of anti-SARS-CoV-2 antibody titers and time of induction to differentiate between severe and mild COVID-19 and could lead to the development of a prognostic biomarker for use early in the course of the illness.

8 Dec 2020

Research shows how targeted microbubbles can carry powerful cancer drugs

New research has shown how microbubbles carrying powerful cancer drugs can be guided to the site of a tumor using antibodies.

8 Dec 2020

UCI researchers develop new technology to rapidly hypermutate antibodies

Using the same strain of yeast that ferments wine and makes dough rise, a team led by University of California, Irvine and Harvard Medical School researchers has developed an in vitro technology that can rapidly hypermutate antibodies.

8 Dec 2020

Researchers use novel technology to prevent destruction of specific proteins inside cells

Columbia researchers have created a new technology using synthetic llama antibodies to prevent specific proteins from being destroyed inside cells.

8 Dec 2020

Studies show IgA antibodies dominate early response to SARS-CoV-2 virus

A new study of more than 150 COVID-19 patients shows that IgA antibodies dominate the early response to the SARS-CoV-2 virus, coming on more quickly and strongly than IgG and IgM antibodies. This is a somewhat unexpected result, as IgM antibodies are usually the immune system's first responders.

7 Dec 2020

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Roswell Park Comprehensive Cancer Center's Francisco J. Hernandez-Ilizaliturri, MD, along with a team of researchers from other institutions, has been investigating a novel therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

7 Dec 2020

Antibody responses to SARS-CoV-2 virus disappear quickly during convalescence, indicates study

A new 5-month longitudinal analysis of 254 COVID-19 patients who displayed a wide range of disease severity - from asymptomatic to deadly illness - suggests that IgA and IgM antibodies to the SARS-CoV-2 virus disappear quickly during convalescence.

7 Dec 2020

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).

7 Dec 2020

Testing for tumor DNA can help predict risk of relapse after transplant in DLBCL patients

Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse.

7 Dec 2020

Paper-based electrochemical sensor can enable rapid detection of SARS-CoV-2

As the COVID-19 pandemic continues to spread across the world, testing remains a key strategy for tracking and containing the virus.

7 Dec 2020

Mount Sinai study shows strong immune response, durability of universal influenza virus vaccine

A vaccine that induces immune responses to a wide spectrum of influenza virus strains and subtypes has produced strong and durable results in early-stage clinical trials in humans, Mount Sinai researchers have found.

7 Dec 2020

Novel form of tau in spinal fluid indicates the stage of Alzheimer’s disease

A novel form of an Alzheimer's protein found in the fluid that surrounds the brain and spinal cord indicates what stage of the disease a person is in, and tracks with tangles of tau protein in the brain, according to a study from researchers at Washington University School of Medicine in St. Louis.

7 Dec 2020

Antibodies News and Research

Evolutionary gene mutation unique to humans may be to blame for risk of advanced cancers

UC Davis Health joins with Novavax to test a new experimental coronavirus vaccine

High-performing multi-immunoassay for early diagnosis and prognosis of COVID-19

Research shows how targeted microbubbles can carry powerful cancer drugs

UCI researchers develop new technology to rapidly hypermutate antibodies

Researchers use novel technology to prevent destruction of specific proteins inside cells

Studies show IgA antibodies dominate early response to SARS-CoV-2 virus

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Antibody responses to SARS-CoV-2 virus disappear quickly during convalescence, indicates study

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

Testing for tumor DNA can help predict risk of relapse after transplant in DLBCL patients

Paper-based electrochemical sensor can enable rapid detection of SARS-CoV-2

Mount Sinai study shows strong immune response, durability of universal influenza virus vaccine

Novel form of tau in spinal fluid indicates the stage of Alzheimer’s disease

D614/G614 variants of SARS-CoV-2 affect neuronal transmission; G614 better at membrane fusion

STE90-C11, a SARS-CoV-2 neutralizing antibody, shows high inhibition of RBD-ACE2 binding

No evidence for risk of vaccine-driven virulence evolution in SARS-CoV-2

High-performance ELISA for serology in mild-moderate non-hospitalized COVID-19

Novel modular design approach to antibody nanocage generation

New biomarker of Alzheimer's may lead to enhanced diagnostic methods

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo